However, fg-SRL treatment has well-recognized positive effects in patients with acromegaly, both in terms of absolute and relative GH and IGF-1 reduction, achievement of biochemical control (about 30-50% of cases), as well as tumor volume reduction (11). The gene discussed is IGF1; the disease is acromegaly.